Congressional Stock Trades & Disclosures
James M. Inhofe is a U.S. Senator, a Republican representing OK. As of January 2021, Bullish Whales has tracked 237 disclosed stock trades across 91 companies, representing $62.9M in disclosed transaction value, each filed publicly under the STOCK Act.
About Inhofe's congressional trading
Inhofe's disclosed activity shows a sell-leaning pattern, with 86 purchases and 151 sales (a buy-to-sell ratio of 0.57). Inhofe has traded CLR, --, and GE most frequently among disclosed positions.
Inhofe's most recent disclosed trade was a sale of Crispr Therapeutics AG (CRSP) from January 2021. Each trade below links to its filing, an estimated price range, and post-trade performance versus the market.
Trading activity
Estimated trading profits
No priced buy disclosures in this window.
No priced buy disclosures in this window.
Based on 78 of 100 disclosed buys with pricing coverage.
Apr 21, 2015 to Jul 14, 2026
Estimated unrealized profit is based on disclosed buy transactions, estimated trade price, and the latest priced-through date. It does not account for later sales, taxes, commissions, slippage, exact execution price, or full portfolio position size. This is descriptive research, not investment advice, and not an allegation of wrongdoing.
Disclosed trades & legislation
| Company | Type | Size | Traded | Est. price | Change |
|---|---|---|---|---|---|
 CRSPCrispr Therapeutics AG | Sell | $1,001 - $15,000 | 05 JAN 2021 | $160.62 | -68.58% |
| CRSPCrispr Therapeutics AG | Sell | $50,001 - $100,000 | 22 DEC 2020 | $170.08 | -70.33% |
 BLKBlackRock Inc | Sell | $50,001 - $100,000 | 15 DEC 2020 | $615.87 | +66.50% |
 AAPLApple Inc. | Sell | $15,001 - $50,000 | 15 JUL 2020 | $94.62 | +232.76% |
 AMZNAmazon.com Inc | Sell | $15,001 - $50,000 | 15 JUL 2020 | $150.44 | +64.51% |
 BAMBrookfield Asset Management Ltd. | Sell | $1,001 - $15,000 | 29 JUN 2020 | N/A | — |
 MSFTMicrosoft Corporation | Sell | $50,001 - $100,000 | 13 APR 2020 | $156.88 | +145.37% |
 VVisa Inc. Class A | Sell | $50,001 - $100,000 | 13 APR 2020 | $161.53 | +120.40% |
| BAMBrookfield Asset Management Ltd. | Sell | $1,001 - $15,000 | 20 MAR 2020 | N/A | — |
 CCitigroup Inc. | Sell | $50,001 - $100,000 | 09 MAR 2020 | $41.17 | +223.74% |
Congressional trading news
The latest news on congressional stock trading, across all members, will appear here as our newsroom publishes it.
James M. Inhofe congressional trading FAQ
Can James M. Inhofe legally trade stocks?
Yes. Members of Congress are permitted to buy and sell stocks, but the 2012 STOCK Act requires them to publicly disclose each transaction, generally within 45 days. Quantellect compiles James M. Inhofe's disclosures so the public can review them.
Where does Quantellect get James M. Inhofe's trading data?
Every trade shown is sourced from official Periodic Transaction Reports filed under the STOCK Act. Amounts are reported as ranges, and estimated prices and post-trade returns are derived from end-of-day market data.
How can I track James M. Inhofe's stock trades?
Quantellect tracks every stock trade James M. Inhofe discloses under the STOCK Act on this page, including the company, the disclosed amount range, and post-trade performance. New filings appear here as they are reported, generally within 45 days of the trade.
How many stock trades has James M. Inhofe disclosed?
Quantellect has tracked 237 disclosed trades by James M. Inhofe across 91 companies.
Which stocks does James M. Inhofe trade most?
James M. Inhofe's most frequently disclosed positions include CLR, --, GE, BAM, and MSFT. The full list of companies and individual filings is shown on this page.
What was James M. Inhofe's most recent stock trade?
James M. Inhofe most recently sold Crispr Therapeutics AG (CRSP) in January 2021, according to public STOCK Act filings tracked by Quantellect.
Browse all members of Congress who trade stocksSee which stocks Congress tradesCongressional trading overview
Trades reflect disclosures filed under the STOCK Act and are provided for informational purposes only, not investment advice. Amounts are ranges from official filings; estimated prices and post-trade returns are derived from end-of-day market data and may be revised as filings are amended.